Share price of
Ltd. dropped 0.31 per cent to Rs 695.2 at 01:21PM (IST) in Tuesday’s trade. The counter hit a high of Rs 703.45 and low of Rs 690.8 so far during the session. The stock had closed at Rs 697.35 in the previous session.
The counter had a total traded volume of 01:21PM shares so far with a turnover of Rs 3.53 crore on BSE. The stock traded at a price-to-earnings multiple of 7.63 and a price-to-book ratio of 2.36.
A higher price-to-earnings ratio shows investors are willing to pay a higher price for per rupee earnings given by the stock because of better future growth expectations.
The price-to-book value indicates the inherent value of a company and is the measure of the price that investors are ready to pay even for no growth in the business.
Aurobindo Pharma Ltd. belongs to the Pharma – Indian industry.
Promotor/FII Holding
Promoters held 51.83 per cent stake in the company as of 30-Sep-2021, while foreign investors and domestic institutional investors ownership stood at 23.41 per cent and 13.82 per cent, respectively.
Key Financials
The company reported consolidated net sales of Rs 5783.29 crore for the quarter ended 30-Jun-2021, down 4.87 per cent from the previous quarter’s Rs 6079.6 crore and down 4.26 per cent from the year-ago quarter’s Rs 6040.37 crore.
Its profit for the latest quarter stood at Rs 769.97 crore, down 1.36 per cent from the same quarter a year ago.
Download The Economic Times News App to get Daily Market Updates & Live Business News.
Share price of Ltd. dropped 0.31 per cent to Rs 695.2 at 01:21PM (IST) in Tuesday’s trade. The counter hit a high of Rs 703.45 and low of Rs 690.8 so far during the session. The stock had closed at Rs 697.35 in the previous session. The counter had a total traded volume of 01:21PM shares so far with a turnover of Rs 3.53 crore on BSE. The stock traded at a price-to-earnings multiple of 7.63 and a price-to-book ratio of 2.36. A higher price-to-earnings ratio shows investors are willing to pay a higher price for per rupee earnings given by the stock because of better future growth expectations. The price-to-book value indicates the inherent value of a company and is the measure of the price that investors are ready to pay even for no growth in the business. Aurobindo Pharma Ltd. belongs to the Pharma – Indian industry. Promotor/FII Holding Promoters held 51.83 per cent stake in the company as of 30-Sep-2021, while foreign investors and domestic institutional investors ownership stood at 23.41 per cent and 13.82 per cent, respectively. Key Financials The company reported consolidated net sales of Rs 5783.29 crore for the quarter ended 30-Jun-2021, down 4.87 per cent from the previous quarter’s Rs 6079.6 crore and down 4.26 per cent from the year-ago quarter’s Rs 6040.37 crore. Its profit for the latest quarter stood at Rs 769.97 crore, down 1.36 per cent from the same quarter a year ago. (What’s moving Sensex and Nifty Track latest market news, stock tips and expert advice on ETMarkets. Also, ETMarkets.com is now on Telegram. For fastest news alerts on financial markets, investment strategies and stocks alerts, subscribe to our Telegram feeds.) Download The Economic Times News App to get Daily Market Updates & Live Business News.